Web Press Release No. 186
Download PDF version of this document.
November 9, 2005
Albany Molecular Research, Inc. Names Lead Independent Director
Albany, NY (November 9, 2005) -- Albany Molecular Research, Inc. (Nasdaq: AMRI) announced today that its board of directors has elected Anthony P. Tartaglia, M.D. as lead independent director.
In this newly created role, Dr. Tartaglia has been assigned several responsibilities designed to enhance board effectiveness, including coordinating and moderating executive sessions of the boardís independent directors, acting as principal liaison between the board and company management, advising the chair regarding scheduling and content of board meetings, and working with the chairman and independent directors in other areas to improve corporate governance. The appointment is consistent with AMRIís high standards of corporate governance, and fills an important need on AMRIís Board as it continues to evolve in a changing regulatory and business environment.
Dr. Tartaglia has served as one of AMRIís directors since 1995. He was a physician at Albany Medical Center Hospital from 1984 to 1998, where he held a number of leadership roles, including dean of Albany Medical College from 1990 to 1995, executive director of the Albany Medical Center Hospital from 1987 to 1990, and senior vice president for patient care from 1984 to 1987. Prior to that, he was chief of medicine at St. Peterís Hospital in Albany from 1975 to 1984. He holds a B.S. in biology from Union College and an M.D. from the University of Rochester Medical School.
Albany Molecular Research, Inc. is a global drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs.
Media Contact: David Albert, Director of Communications, Albany Molecular Research, Inc., 518-464-0279, ext. 2229
Investor Contact: P. Curtis Schenck, Investor Relations Manager, Albany Molecular Research, Inc., 518-464-0279, ext. 2933
Return to Main Press Release Page